An interventional study of Vitamin D3 ( Colecalciferol) in Dental Implant, sponsored by Air Force Military Medical University, China. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Air Force Military Medical University, China · Not applicable, Interventional, and Treatment
This study aims to evaluate whether vitamin D3 supplementation can promote dental implant osseointegration by increasing serum sphingosine-1-phosphate (S1P) levels. Sixty patients scheduled for dental implant surgery between July 2025 and December 2026 will be enrolled. Before surgery, baseline clinical data, cone-beam computed tomography (CBCT) imaging data, and blood samples for serum S1P measurement by ELISA will be collected. Based on baseline S1P levels, 40 patients with low S1P levels will be selected and randomized into a control group and an intervention group, with the intervention group receiving daily vitamin D3 supplementation (800 IU) from immediately after surgery until 3 months postoperatively. At the 3-month follow-up, CBCT images will be acquired again and compared with baseline to assess osseointegration, implant stability will be evaluated by measuring implant stability quotient (ISQ) values, and serum S1P levels will be re-measured. Statistical analysis will be performed using R software. The primary endpoint is the effect of vitamin D3 supplementation on dental implant osseointegration, while secondary endpoints include changes in serum S1P levels, implant stability (ISQ), and safety.
Air Force Military Medical University, China is the lead sponsor of 178 studies on the registry; 37 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:Healthy adults aged 18 years or older.
Patients with a single missing tooth requiring implant restoration.
Intact lingual or palatal bone wall at the edentulous site, with sufficient bone volume for implant placement confirmed by preoperative CBCT evaluation.
Healthy opposing and adjacent teeth, with sufficient interocclusal space and normal occlusion and overbite relationships.
Good treatment compliance. -
Exclusion Criteria:Severe acute or chronic inflammation at the implant site.
Insufficient mesiodistal width for implant placement.
Presence of poor oral habits such as heavy smoking (>10 cigarettes/day), bruxism, or periodontal disease.
Pregnant or lactating women.
Poor general health condition, unable to tolerate surgery.
Patients currently undergoing orthodontic treatment.
Patients taking medications affecting bone metabolism.
Allergy to Vitamin D3.
Any medical condition contraindicated for Vitamin D3 supplementation.
-
Patients with high baseline S1P levels receiving standard postoperative care without vitamin D3 supplementation.
Patients with low baseline S1P levels receiving standard postoperative care without vitamin D3 supplementation.
Patients with low baseline S1P levels receiving daily oral vitamin D3 supplementation (800 IU) for 3 months postoperatively.
Dietary Supplement: Vitamin D3 ( Colecalciferol)
Oral vitamin D3 supplementation at a dose of 800 IU daily for 3 months postoperatively.
Effect of Vitamin D3 Supplementation on Dental Implant Osseointegration
Assessment of peri-implant bone changes and osseointegration using cone-beam computed tomography (CBCT) at 3 months postoperatively compared with baseline.
Time frame: Baseline and 3 months postoperatively
Baseline and 3 months postoperatively
Change in serum S1P levels measured by ELISA from baseline to 3 months postoperatively.
Time frame: Baseline and 3 months postoperatively
Implant Stability Quotient (ISQ)
Measurement of implant stability quotient (ISQ) values to evaluate implant stability at 3 months postoperatively.
Time frame: 3 months postoperatively
No study locations are listed for this record.
Plan to share: No — The individual participant data (IPD) will not be shared due to privacy and ethical restrictions. The data contain sensitive patient information, and sharing them would compromise participant confidentiality. Additionally, national and institutional regulations restrict the sharing of clinical data with external parties or international databases. De-identified data may be available from the corresponding author upon reasonable request and with approval from the institutional ethics committee.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cholecalciferol
Air Force Military Medical University, China →